Skip to main content

Caxton Corp

SEC CIK
0001388551
Latest filing
Aug 13, 2026

Holdings in Q4 2023

Holdings as of Dec 31, 2023, filed Feb 14, 2024. Long positions only; changes compare share counts with Q3 2023.

Institution overview
Positions
12
+3 vs. Q3 2023
Portfolio value
$18.5M
−$7.80M (−29.6%) vs. Q3 2023
Filed
Feb 14, 2024
SEC
Holdings of Caxton Corp in Q4 2023
SecurityClassSharesValue% of portfolioShare changeActionHistory
XERSXeris Biopharma Holdings, Inc.COM5,641,920$13.3M71.6%00.0%UnchangedHistory
SVRASavara IncCOM353,441$1.66M9.0%−2,960,161−89.3%ReducedHistory
RZLTRezolute, Inc.COM NEW1,318,967$1.31M7.1%00.0%UnchangedHistory
SPYSPDR S&P 500 ETF TrustETF1,322$628.1K3.4%+1,322NewHistory
MTEMMolecular Templates, Inc.COM NEW136,866$510.5K2.8%00.0%UnchangedHistory
BRK.BBerkshire Hathaway IncStock1,035$369.3K2.0%+1,035NewHistory
APGEApogee Therapeutics, Inc.COM7,353$205.4K1.1%−5,119−41.0%ReducedHistory
ABVXAbivax S.A.SPONSORED ADS16,743$179.1K1.0%+16,743NewHistory
LXEOLexeo Therapeutics, Inc.COM10,319$138.5K0.7%+10,319NewHistory
HARPHarpoon Therapeutics, Inc.COM NEW13,176$129.3K0.7%+13,176NewHistory
CMPXCompass Therapeutics, Inc.COM43,465$67.8K0.4%−43,308−49.9%ReducedHistory
ALLKAllakos Inc.COM24,710$67.5K0.4%−24,619−49.9%ReducedHistory

Sold out since Q3 2023 (2)

Positions held at the end of Q3 2023 that are gone from this filing.

Positions of Caxton Corp sold out since Q3 2023
SecurityClassShares in Q3 2023Value in Q3 2023% of portfolio in Q3 2023History
ACRSAclaris Therapeutics, Inc.COM19,473$133.4K0.5%History
ELEVElevation Acquisition Group Inc.COM21,813$14.5K0.1%History